Logo of

Nils H. Thoennissen, MD, Neurologist, Stem Cell Therapy - Munich, Germany

Ottostraße 3-5, 80333, Munich, Germany Munich, Germany
Associated Center: Stroke Recovery Treatment Center in Germany
Speciality: Neurologist, Stem Cell Therapy,
Languages: English
Focus Area: Nils H. Thoennissen, MD | Stem Cell Therapy | Neurological Disorder | Munich | Germany

About - Nils H. Thoennissen, MD

Dr Nils H. Thoennissen

With more than 20 years of experience in evidence-based medicine and over 14 years of clinical experience in chemotherapy including blood transfusions, as well as stem cell transplantation, Dr. Thoennissen is an international specialist in cancer, chronic degenerative diseases, and regenerative medicine with a doctoral thesis in neurological research, graded with “summa cum laude”.
 
Dr. Thoennissen is an honorable member of the Demarest Clinic's medical advisory board. Before joining CBC Health Stroke Recovery Treatment, he spent 20 years in evidence-based medicine and over 14 years in chemotherapy, including blood transfusions and stem cell transplantation.

Dr. Thoennissen went to the United Kingdom to further his education after graduating from the University of Muenster in Germany. He successfully completed his post-graduate studies at Cardiff University School of Medicine in the United Kingdom. He did his postdoctoral research in Hematology/Oncology at Cedars-Sinai Medical Center, UCLA, Los Angeles, from 2008 to 2010.

Dr. Thoennissen, MD, worked as a consultant in the Hematology/Oncology Department and the Emergency Department at the University Clinic of Hamburg-Eppendorf in Germany. His remarkable presence as an investigator of several clinical studies related to the treatment of blood disorders and cancer has earned him the title of the eminent contributor.

As a senior physician and author, Dr. Nils has over 40 impressive clinical and scientific publications in various peer-reviewed international journals. He received numerous awards from prestigious universities and other organizations in Germany and America, including the Travel Award 51st and 52nd Congress of the American Society of Hematology in 2009 and 2010.

contact us

Education

Qualifications

  • Westfälische-Wilhelms-University of Muenster, Muenster, Germany
  • Cardiff University School of Medicine, Cardiff, Great Britain
  • Johannes Gutenberg-University, Mainz, Germany
  • Cedars-Sinai-Medical-Center, UCLA, Los Angeles, USA Residency and Fellowship
  • Resident Department of Hematology, Oncology & Transplantation, University Hospital of Münster, Germany
  • IZKF-research fellowship Laboratory of Molecular Hematology, University Hospital of Münster, Germany
  • DFG-research fellowship (2 years) Division of Hematology/Oncology, Cedars-Sinai Medical-Center, UCLA, Los Angeles, USA
  • Resident Department of Hematology, Oncology & Transplantation, University Hospital of Münster, Germany

Career Highlights

  • More than 14 years clinical experience in chemotherapy including blood transfusions, as well as stem cell transplantation.
  • Spent 3 years in Los Angeles, USA, at Cedars-Sinai-Medical-Center, UCLA for research.
  • Author of more than 40 high-ranking clinical and scientific publications in peer-reviewed international journals.
  • Investigator and Sub-Investigator of several clinical studies.
  • Past consultant of Hem/Onc Dpt. and Emergency Dpt. in the University Clinic of Hamburg-Eppendorf, Germany

contact us

Membership

Awards

  • Doctoral thesis, University of Münster, Germany (WWU) summa cum laude
  • 1st Price for Innovation, University Hsp. of Münster, Germany 09/2006
  • Travel Award 51st Congress of American Society of Hematology (ASH) 12/2009
  • Travel Award 52nd Congress of American Society of Hematology (ASH) 12/2010
  • Sponsorship Award for leukemic research University of Münster, Germany (WWU) 06/2012
  • Best Poster Award – Society for Gastroenterology, Germany „Nicotinamide and its therapeutical effects on colitis in a mouse model“ 12/2012
  • Best of DGHO – Translational Medicine „Exome sequencing of paired chronicblast phase samples in myeloproliferative neoplasms reveals high frequency of rare germline sequence variants In TYK2 and novel blast phase-restricted mutations“ 10/2014

Publications

  1. Kleef R, Nagy R, Baierl A, Bacher V, Bojar H, McKee DL, Moss R, Thoennissen NH, Szász M, Bakacs T. Low-dose ipilimumab plus nivolumab combined with IL-2 and hyperthermia in cancer patients with advanced disease: exploratory findings of a case series of 131 stage IV cancers – a retrospective study of a single institution. Cancer Immunol Immunother. 2020 Nov 5.
  2. Thoennissen GB, Görlich D, Bacher U, Aufenberg T, Hüsken AC, Hansmeier AA, Evers G, Mikesch JH, Fritz F, Bokemeyer C, Müller-Tidow C, Stelljes M, Mesters RM, Krug U, Kropff MH, Thoennissen NH*, Berdel WE.Autologous Stem Cell Transplantation in Multiple Myeloma in the Era of Novel Drug Induction: A Retrospective Single-Center Analysis. Acta Haematol. 2017;137(3):163-172.
  3. Pohlen M, Thoennissen NH*, Braess J, Thudium J2, Schmid C3, Kochanek M, Kreuzer KA, Lebiedz P, Görlich D, Gerth HU, Rohde C, Kessler T, Müller-Tidow C, Stelljes M, Büchner T, Schlimok G, Hallek M, Waltenberger J, Hiddemann W, Berdel WE, Heilmeier B, Krug U. Patients with Acute Myeloid Leukemia Admitted to Intensive Care Units: Outcome Analysis and Risk Prediction. PLoS One. 2016 Aug 30;11(8):e0160871.
  4. Karagiannis P, Guth N, Thoennissen GB, Bern C, Sperveslage J, Oschlies I, Bokemeyer, C, Klapper W, Wardelmann E, Thoennissen NH: Alveolar rhabdomyosarcoma confined to the bone marrow with no identifiable primary tumour using FDG-PET/CT. Clin Sarcoma Res. 2015; 5: 24.
  5. Thoennissen NH, Clauditz T, Ittrich H, Stahl R, Bokemeyer C, Klose H. 55-year old woman, smoking, with obvious exhaustion, fever and hemoptysis. Dtsch Med Wochenschr. 2014 Oct;139(41):2073-4.
  6. Bettenworth D, Nowacki TM, Ross M, Kyme P, Schwammbach D, Kerstiens L, Thoennissen GB, Bokemeyer C, Hengst K, Berdel WE, Heidemann J, Thoennissen NH. Nicotinamide treatment ameliorates the course of experimental colitis mediated by enhanced neutrophil-specific antibacterial clearance. Mol Nutr Food Res. 2014;58(7):1474-90.
  7. Hascher A, Haase AK, Hebestreit K, Rohde C, Klein HU, Rius M, Jungen D, Witten A, Stoll M, Schulze I, Ogawa S, Wiewrodt R, Tickenbrock L, Berdel WE, Dugas M, Thoennissen NH*, Müller-Tidow C. DNA methyltransferase inhibition reverses epigenetically embedded phenotypes in lung cancer preferentially affecting polycomb target genes. Clin Cancer Res. 2014 Feb 15;20(4):814-26.
  8. Mikesch JH, Kuhlmann M, Demant A, Krug U, Thoennissen GB, Schmidt E, Kessler T, Schliemann C, Pohlen M, Mohr M, Evers G, Köhler G, Wessling J, Mesters R, MüllerTidow C, Berdel WE, Thoennissen NH. DexaBEAM versus ICE salvage regimen prior to autologous transplantation for relapsed or refractory aggressive peripheral T cell lymphoma: a retrospective evaluation of parallel patient cohorts of one center. Ann Hematol. 2013 Aug;92(8):1041-48.
  9. Kyme P, Thoennissen NH*, Tseng CW, Thoennissen GB, Wolf AJ, Shimada K, Krug UO, Lee K, Müller-Tidow C, Berdel WE, Hardy WD, Gombart AF, Koeffler HP, Liu GY. C/EBPε mediates nicotinamide-enhanced clearance of Staphylococcus aureus in mice. J Clin Invest. 2012 Sep 4;122(9):3316-29.
  10. Thoennissen GB, Thoennissen NH*, Fritz F, Hilbig A, Kerkhoff A, Liersch R, Krug U, Koschmieder S, Müller-Tidow C, Mesters R, Kropff M, Berdel WE. POEMS syndrome treated with melphalan high-dose therapy and autologous blood stem cell transplantation: a single-institution experience. Ann. Hematol. 2012 Sep;91(9):1419-25.
  11. Thoennissen NH, Thoennissen GB, Nabavi-Nouis S, Abbassi S, Sauer T, Doan NB, Gery S, Müller-Tidow C, Said JW, Koeffler HP. The transcription factor C/EBPalpha and a critical circadian clock downstream target gene, PER2, are highly deregulated in diffuse large B-cell lymphoma. Leuk Lymphoma. 2012 Aug;53(8):1577-85.
  12. Thoennissen NH, Lasho T, Thoennissen GB, Ogawa S, Tefferi A, Koeffler HP. Novel CUX1 missense mutation in association with 7q- at leukemic transformation of MPN. Am J Hematol. 2011;86(8):703-05.
  13. Lee DH, Thoennissen NH*, Goff C, Iwanski GB, Forscher C, Doan NB, Said JW, Koeffler HP. Synergistic effect of low-dose cucurbitacin B and low-dose methotrexate for treatment of human osteosarcoma. Cancer Lett. 2011 Jul 28;306(2):161-70.
  14. Akagi T, Thoennissen NH*, George A, Crooks G, Song JH, Okamoto R, Nowak D, Gombart AF, Koeffler HP. In Vivo Deficiency of Both C/EBPβ and C/EBPε Results in Highly Defective Myeloid Differentiation and Lack of Cytokine Response. PLoS One. 2010;5(11):e15419.
  15. Iwanski GB, Lee DH, En-Gal S, Doan NB, Castor B, Vogt M, Toh M, Bokemeyer C, Said JW, Thoennissen NH*, Koeffler HP. Cucurbitacin B, a novel in vivo potentiator of gemcitabine with low toxicity in the treatment of pancreatic cancer. Br J Pharmacol. 2010;160(4):998-1007
  16. Thoennissen NH, Krug UO, Lee DH, Kawamata N, Iwanski GB, Lasho T, Weiss T, Nowak D, Koren-Michowitz M, Kato M, Sanada M, Shih LY, Nagler A, Raynaud SD, Müller-Tidow C, Mesa R, Haferlach T, Gilliland DG, Tefferi A, Ogawa S, Koeffler HP. Prevalence and prognostic impact of allelic imbalances associated with leukemic transformation of Philadelphia chromosome-negative myeloproliferative neoplasms. Blood. 2010;115(14):2882-90.
  17. Thoennissen NH, O’Kelly J, Lu D, Iwanski GB, La DT, Abbassi S, Leiter A, Karlan B, Mehta R, Koeffler HP. Capsaicin causes cell-cycle arrest and apoptosis in ER-positive and -negative breast cancer cells by modulating the EGFR/HER-2 pathway. Oncogene. 2010;29(2):285-96. 5
  18. Thoennissen NH, Iwanski GB, Doan NB, Okamoto R, Lin P, Abbassi S, Song JH, Yin D, Toh M, Xie WD, Said JW, Koeffler HP. Cucurbitacin B induces apoptosis by inhibition of the JAK/STAT pathway and potentiates antiproliferative effects of gemcitabine on pancreatic cancer cells. Cancer Res. 2009;69(14):5876-84.
  19. Thoennissen NH, Keyvani K, Voelker HU, Bremer J, Krug U, Müller-Tidow C, Koch P, Müller-Hermelink HK, Berdel WE. Splenic marginal zone lymphoma: transformation to diffuse large B-cell lymphoma with isolated cerebral manifestation. J Clin Oncol. 2008;26(27):4509-11.
  20. Thoennissen NH, Schliemann C, Hungermann D, Bremer J, Juergens KU, Semik M, Müller-Tidow C, Zuehlsdorf M, Berdel WE. Solitary plasmacytoma of the lung with coexisting sarcoid-like lesions. Ann Hematol. 2008;87(5):417-20.
  21. Thoennissen NH, Schliemann C, Brunnberg U, Schmidt E, Staebler A, Stegger L, Bremer C, Schleicher C, Mesters RM, Müller-Tidow C, Berdel WE. Chemotherapy in metastatic malignant triton tumor: report on two cases. Oncol Rep. 2007;18(4):763-67.
  22. Thoennissen NH, Baumann C, Kelsch R, Albrecht O, Müller-Tidow C, Sibrowski W, Berdel WE, Mesters R: Heparin-Induced Thrombocytopenia vs. Plasmapheresis-Induced Platelet Loss in a Case of Thrombotic Thrombocytopenic Purpura. Transfusion Medicine and Hemotherapy. 2007;34:74-77.
  23. Thoennissen NH, Allroggen A, Ritter M, Dittrich R, Schmid C, Schmid HH, Ringelstein EB, Nabavi DG. Influence of inflammation and pump dynamic on cerebral microembolization in patients with Continuous-Flow DeBakey LVAD. ASAIO J. 2006;52(3):243-47.
  24. Thoennissen NH, Schneider M, Allroggen A, Ritter M, Dittrich R, Schmid C, Scheld HH, Ringelstein EB, Nabavi DG. High level of cerebral microembolization in patients supported with the DeBakey left ventricular assist device. J Thorac Cardiovasc Surg. 2005;130(4):1159-66.
  25. Thoennissen NH, Allroggen A, Dittrich R, Ritter M, Schmid C, Scheld HH, Ringelstein EB, Nabavi DG. Can Doppler time domain analysis of microembolic signals discriminate between gaseous and solid microemboli in patients with left ventricular assist device? Neurol Res. 2005;27(7):780-84.
  26. Mikesch JH, Schwammbach D, Hartmann W, Schmidt LH, Schliemann C, Angenendt L, Wiewrodt R, Marra A, Thoennissen NH, Wardelmann E, Köhler G, Lenz G, Müller-Tidow CM, Berdel WE and Arteaga MF. Reptin drives tumour progression and resistance to chemotherapy in non-small cell lung cancer. Eur Respir J. 2018 May 31. pii: 1701637.
  27. Bulk E, Ay AS, Hammadi M, Schölhaas S, Hascher A, Rohde C, Thoennissen NH, Wiewrodt R, Schmidt E, Klein HU, Dugas M, Berdel WE, Müller-Tidow C, Schwab A. Epigenetic dysregulation of Kca 3.1 channels induces poor prognosis in lung cancer. Intern J Cancer. 2015;137(6):1306-17.
  28. Nowak D, Liem NLM, Mossner M, Papa RA, Nowak V, Jann JC, Kawamata N, Okamoto R, Thoennissen NH, Kato M, Hofmann WK, Ogawa S, Lock RB, Koeffler HP. Variegated clonality and rapid emergence of new molecular lesions in xenografts of acute lymphoblastic leukemia are associated with drug resistance. Exp Hematol. 2015;43(1):32-43.
  29. Nowacki TM, Brückner M, Tepasse P, Pott F, Thoennissen NH, Hengst K, Ross M, Bettenworth D. The risk of colorectal cancer in patients with ulcerative colitis. Dig Dis Science, 2015;60(2):492-501.
  30. Kanda J, Mori K, Kawabata H, Kuwabara T, Mori KP, Imamaki H, Kasahara M, Yokoi H, Mizumoto C, Thoennissen NH, Koeffler HP, Barasch J, Takaori-Kondo A, Mukoyama M, Nakao K. An AKI biomarker lipocalin 2 in the blood derives from the kidney in renal injury but from neutrophils in normal and infected conditions. Clin Exp Nephrol. 2015;19(1):99- 106.
  31. Schmidt LH, Görlich D, Spieker T, Rohde C, Schuler M, Mohr M, Humberg J, Sauer T, Thoennissen NH, Huge A, Voss R, Marra A, Faldum A, Müller-Tidow C, Berdel WE, Wiewrodt R. Prognostic Impact of Bcl-2 Depends on Tumor Histology and Expression of MALAT-1 lncRNA in Non-Small-Cell Lung Cancer. J Thorac Oncol. 2014;9(9):1294-304
  32. Evers G, Pohlen M, Berdel WE, Thoennissen NH, Titze U, Köhler G, Weckesser M, Anthoni C, Mesters RM. Visceral leishmaniasis clinically mimicking lymphoma. Ann Hematol. 2014;93(5):885-7.
  33. Aribi A, Gery S, Lee DH, Thoennissen NH, Thoennissen GB, Alvarez R, Ho Q, Lee K, Doan NB, Chan KT, Toh M, Said JW, Koeffler HP. The triterpenoid cucurbitacin B augments the antiproliferative activity of chemotherapy in human breast cancer. Int J Cancer. 2013;132(12):2730-37.
  34. Gerth HU, Pohlen M, Thoennissen NH, Suwelack B, Pavenstädt HJ, Störkel S, Abbas M, Spieker T, Thölking G. Two papillary renal cell carcinomas of different origin following renal transplantation. Oncol Lett. 2012;4(1):80-82.
  35. Agrawal-Singh S, Isken F, Agelopoulos K, Klein HU, Thoennissen NH, Koehler G, Hascher A, Baeumer N, Berdel WE, Thiede C, Ehninger G, Becker A, Schlenke P, Wang Y, McClelland M, Krug U, Koschmieder S, Buechner T, Yu DY, Singh SV, Hansen K, Serve H, Dugas M, Mueller-Tidow C. Genome wide analysis of histone H3 acetylation patterns in AML identifies PRDX2 as an epigenetically silenced tumor suppressor gene. Blood. 2012;119(10):2346-57.
  36. Müller-Tidow C, Klein HU, Hascher A, Isken F, Tickenbrock L, Thoennissen NH, Agrawal-Singh S, Tschanter P, Disselhoff C, Wang Y, Becker A, Thiede C, Ehninger G, Zur Stadt U, Koschmieder S, Seidl M, Müller FU, Schmitz W, Schlenke P, McClelland M, Berdel WE, Dugas M, Serve H; on behalf of the Study Alliance Leukemia. Profiling of histone H3 lysine 9 trimethylation levels predicts transcription factor activity and survival in acute myeloid leukemia. Blood. 2010;116(18):3564-71.
  37. Agrawal-Singh S, Koschmieder S, Gelsing S, Stocking C, Stehling M, Thiede C, Thoennissen NH, Köhler G, Valk PJ, Delwel R, Mills K, Bäumer N, Tickenbrock L, Hansen K, Berdel WE, Müller-Tidow C, Serve H. Pim2 cooperates with PML-RARalpha to induce acute myeloid leukemia in a bone marrow transplantation model. Blood. 2010;115(22):4507-16.
  38. Nowak D, Ogawa S, Müschen M, Kato M, Kawamata N, Meixel A, Nowak V, Kim HS, Kang S, Paquette R, Chang MS, Thoennissen NH, Mossner M, Hofmann WK, Kohlmann A, Weiss T, Haferlach T, Haferlach C, Koeffler HP. SNP array analysis of tyrosine kinase inhibitor-resistant chronic myeloid leukemia identifies heterogeneous secondary genomic alterations. Blood. 2010;115(5):1049-53.
  39. Schmidt E, Thoennissen NH, Rudat A, Bieker R, Schliemann C, Mesters RM, Zühlsdorf M, Müller-Tidow C, Berdel WE. Use of palifermin for the prevention of high-dose methotrexate-induced oral mucositis. Ann Oncol. 2008;19(9):1644-49.
  40. Schliemann C, Bieker R, Thoennissen NH, Gerss J, Liersch R, Kessler T, Büchner T, Berdel WE, Mesters RM. Circulating angiopoietin-2 is a strong prognostic factor in acute myeloid leukemia. Leukemia. 2007;21(9):1901-06.
  41. Zahiragic L, Schliemann C, Bieker R, Thoennissen NH, Burow K, Kramer C, Zühlsdorf M, Berdel WE, Mesters RM. Bevacizumab reduces VEGF expression in patients with relapsed and refractory acute myeloid leukemia without clinical antileukemic activity. Leukemia. 2007;21(6):1310-12.
contact us

Stroke Recovery Treatment Center in Germany reviews

  • User Profile Image

    Anonymous

    Take a look at Christy´s inspiring story of improvement  after Stroke via Umbilical Cord Blood Treatment in 2020 at top clionic in Munich.

    Dec 20 2021

Stem Cell Therapy Related Videos

Watch our videos content to learn about their story

CABO STEM CELL CENTER

Stem Cell Therapy

Cabo Stem Cell Center

Cabo San Lucas, Mexico

Breathe Easy: Laurie’s Journey with Regenerative Medicine for Asthma at Regenestem in Fort Lauderdale

Stem Cell Therapy

Regenestem Fort Lauderdale, USA

Fort Lauderdale, United States

A Journey to Recovery: Daniel's Story of Stem Cell Therapy in Monterrey, Mexico by Stem Solutions

Stem Cell Therapy

Stem Solutions

Monterrey,San Pedro Garza Garcia, Mexico

Televisa Quintana Roo Interview: Dr. Adriana Gudiño Discusses Stem Cell Therapy in Cancun, Mexico – Understanding Placental Mesenchymal Cells

Stem Cell Therapy

Clinica MER Cancun

Cancun, Mexico

Stem Cell Therapy Related Packages

Learn Medical Packages To Get The Best Suitable For Your Medical Need

Stem Cells and PRP Knee Cartilage Rejuvenation Chondroplasty Package in Bengaluru, India by Giostar

Price starting from $4750.0

Stem Cells and PRP Knee Cartilage Rejuvenation Chondroplasty Package in Bengaluru, India by Giostar

GIOSTAR Hospital Bengaluru

  • Stem Cell Therapy

Bangalore,Bengaluru, India

Stem Cells and PRP Knee Cartilage Rejuvenation Microfracture Package in Bengaluru, India by Giostar

Price starting from $4750.0

Stem Cells and PRP Knee Cartilage Rejuvenation Microfracture Package in Bengaluru, India by Giostar

GIOSTAR Hospital Bengaluru

  • Stem Cell Therapy

Bangalore,Bengaluru, India

Stem Cell Treatment for Autism Package in Malacky, Slovakia with IV Procedure Only by CellCenter

Price starting from $5500.0

Stem Cell Treatment for Autism Package in Malacky, Slovakia with IV Procedure Only by CellCenter

CellCenter

  • Stem Cell Therapy

Bratislava,Malacky, Slovakia

Stem Cell Therapy for Lupus Package in Tijuana, Mexico by CellsTime

Price starting from $4000.0

Stem Cell Therapy for Lupus Package in Tijuana, Mexico by CellsTime

CellsTime Clinique Tijuana

  • Stem Cell Therapy

Tijuana, Mexico

Stem Cell Therapy Related Experiences

Hear Their Success Story In Their Medical Journey

Stem Cell Therapy in India for Diabetes Type 1

Price starting from $9000.0

Stem Cell Therapy in India for Diabetes Type 1

  • Stem Cell Treatment for Diabetes, Stem Cell Therapy

India

Stem Cell Treatments for Hair Loss in Thailand

Price starting from $1900.0

Stem Cell Treatments for Hair Loss in Thailand

  • Stem Cell Treatment for Hair Loss, Stem Cell Therapy

Thailand

Stem Cell Therapy for Knee Arthritis in Thailand

Price starting from $1900.0

Stem Cell Therapy for Knee Arthritis in Thailand

  • Stem Cell Therapy for Knee Arthritis, Stem Cell Therapy

Thailand

Stem Cell Therapy in Europe

Price starting from $8700.0

Stem Cell Therapy in Europe

  • Stem Cell Therapy

Europe

PlacidWay.com provides information and travel related services. We do not provide health care services. We provide information solely for informational purposes and do not endorse any particular health care provider or facility or any particular health care service or treatment. We are not affiliated with any health care provider or service and we are not responsible for any health care service. Please consult with your own domestic licensed health care provider before seeking the services of any health care provider you learn about via our site

Share this listing